Developer docs
API playgroundTry for free, no card

Search company profiles

Vizgen

Full company profile

uuid00006sr

Namestring
Vizgen
Legal namestring
Vizgen, Inc.
Websiteurl
vizgen.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Vizgen is a privately held spatial multiomics company headquartered in Waltham, Massachusetts, with R&D and lab services in Cambridge, MA. Founded in 2019 to commercialize MERFISH technology exclusively licensed from Harvard University, the company has built an integrated platform that combines spatial transcriptomics (MERFISH 2.0 chemistry on the MERSCOPE Ultra instrument) with spatial proteomics (InSituPlex multiplex immunofluorescence inherited from the October 2024 Ultivue merger), supported by AI-driven analysis (STARVUE) and an open-source cell-segmentation tool (VPT). The company sells capital equipment, recurring reagents and consumables, software licenses, professional services, and runs a global Certified Service Provider (CSP) network, with more than 200 MERSCOPE platforms installed across academic, healthcare, and biopharma customers worldwide and 400+ peer-reviewed MERFISH publications.

Vizgen serves four primary customer segments: academic neuroscience researchers, oncology and immuno-oncology labs, cell-atlasing consortia (including the Human Cell Atlas), and biopharma drug discovery and translational teams, with a secondary base of core facilities and CSPs. The go-to-market combines direct enterprise sales in the UK, BENELUX, Nordics, France, Germany, Austria, and Singapore with a global distributor network covering 14+ countries; revenue is generated through one-time instrument sales, recurring consumables and panel pull-through on the installed base, per-instrument software licensing (EULAs for MERSCOPE Vizualizer and instrument software), and project-based spatial omics services including a newly launched Volumetric Tissue Mapping offering. The company is venture-backed (most recent $48 million Series E in January 2026 led by ARCH Venture Partners) with institutional investors including ARCH, M Ventures, Northpond Ventures, Tao Capital Partners, and Novalis LifeSciences, and is led by CEO Rob Carson following the Ultivue merger.

The business model is a classic razor-and-blade life-sciences tools franchise anchored by a recurring consumables stream tied to the installed MERSCOPE instrument base, complemented by growing services revenue and a software-plus-AI roadmap (cloud-based MERFISH 2.0 analysis, an AI Analysis Agent for end-to-end workflow automation, and continued expansion of pre-designed gene and protein panels). The 2025 settlement of the 10x Genomics / Harvard patent litigation removed a major commercialization overhang, and the CEO has publicly stated Vizgen is on a path to profitability, though no specific timeline has been disclosed. Notable scientific and commercial endorsements come from the Allen Institute for Brain Science, UCSD / Ludwig Institute for Cancer Research, Mayo Clinic, Weizmann Institute of Science, St. Jude Children's Research Hospital, and SickKids Research Institute.

Short descriptiontext

Vizgen provides integrated spatial multiomics platforms combining MERFISH 2.0 transcriptomics and InSituPlex proteomics on the MERSCOPE Ultra instrument, serving academic researchers, biopharma drug discovery teams, and core facilities worldwide.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
spatial transcriptomics platforms, spatial proteomics assays, single-cell spatial genomics, multiplex immunofluorescence instruments, spatial multiomics instruments
Industry4 codes
PRIMARYHLAGANAC
Single-Cell & Spatial Omics Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGANAE
Transcriptomics & Gene Expression Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAF
Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Spatial Multiomics Instruments
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model5 records
1Instrument Sales (Capital Equipment)
TypeHardware Sales
Description

One-time sale of the MERSCOPE Ultra spatial genomics instrument to research institutions, biopharma, and certified service providers; gated by quote-based enterprise sales motion.

vizgen.com
2Reagents and Consumables
TypeSubscription Recurring
Description

Recurring revenue from MERSCOPE Gene Imaging Kits, MERSCOPE Slides, sample preparation kits, verification kits, InSituPlex protein assays, and pre-designed gene panels. Consumables attach to the installed MERSCOPE instrument base, providing high-margin pull-through.

vizgen.com
3Software Licensing
TypeOne Time License
Description

Per-instrument and enterprise licensing for MERSCOPE Vizualizer visualization software (EULA) and MERSCOPE instrument/image-processing software (EULA), including Early Release purchase and license terms.

vizgen.com
4Spatial Omics Lab Services
TypeProfessional Services
Description

Professional services including spatial transcriptomics analysis services, spatial proteomics/assay development services, custom panel design services, and the new Volumetric Tissue Mapping service offering project-based access to MERFISH data generation.

vizgen.com
5Certified Service Provider Network Revenue
TypeManaged Services
Description

Recurring revenue from CSP program participation: certified labs receive special CSP pricing tiers in exchange for delivering Vizgen spatial biology services to end customers, with co-branding opportunities to drive demand.

vizgen.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Pricing details1 tier
1Quote-based pricing across all product categories; not publicly disclosed
ModelOtherBilling cadenceAnnual
Notes

Pricing available via direct sales engagement; HCA member discount available for eligible institutions; pre-designed panels positioned as more cost-efficient than fully custom panels for pilot and large-scale studies.

vizgen.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 7 records shown
1MERSCOPE
Description

Vizgen's flagship spatial transcriptomics platform / instrument family, including the MERSCOPE Ultra high-throughput instrument.

vizgen.com
+6 more records
Core offering1 text field

Vizgen develops and sells an integrated spatial multiomics platform for research and translational use, anchored by the MERSCOPE Ultra instrument running MERFISH 2.0 chemistry for in situ single-cell spatial transcriptomics and complemented by InSituPlex multiplex immunofluorescence assays for spatial proteomics, STARVUE AI analysis, and Vizgen Post-processing Tool (VPT) cell segmentation. The company also markets gene panels (pre-designed and custom), reagents and consumables, visualization and analysis software, and fee-for-service spatial omics lab services.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 200+ MERSCOPE Platforms installed globally (largest spatial biology install base)
+4 more records
Product overview1 text field

Vizgen offers an integrated spatial multiomics platform combining spatial transcriptomics and spatial proteomics, built on its proprietary MERFISH 2.0 chemistry and InSituPlex assays and powered by the AI-driven STARVUE analysis and Vizgen Post-processing Tool (VPT). The core instrument is the MERSCOPE Ultra Platform (with the original MERSCOPE Platform and MERSCOPE Vizualizer Software as the visualization layer), which runs Pre-designed Panels and customizable Add-on Gene Panels (including Mouse PanNeuro Cell Type, Pan Human, Pan Mouse, Human Brain, Human Breast Cancer, Human ImmunoOncology, Human Colon/Lung/Liver/Kidney Cancer, Mouse Transcription Factor A/B, and Tumor EMT/Inflammation/Cardiovascular panels in development). The proteomics arm uses InSituPlex multiplex immunofluorescence with OmniVUE pre-designed panels and U-VUE custom panels. Supporting offerings include the open-source VPT cell segmentation tool (with Cellpose-SAM and InstanSeg plugins), the Vizgen Gene Panel Design Portal, Volumetric Tissue Mapping services for 3D thick-tissue analysis, and Spatial Transcriptomics and Spatial Proteomics Lab Services for end-to-end project support. Together, these tools allow researchers to map up to 1,000 RNA targets and quantify proteins in whole-slide FFPE or fresh frozen tissue at single-cell resolution.

Product and service1 record
1MERSCOPE Ultra Platform
Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership29 partners
Strategic tierFlagshipTypeTechnology or IntegrationAnnounced on2025-06-03
Description

Strategic partnership to streamline spatial biology workflows and deliver biomarker-detecting imaging. Collaboration centers on immunofluorescence imaging using Hamamatsu's MoxiePlex platform integrated with Vizgen's spatial transcriptomics and proteomics solutions. The partnership is intended to help translate multiplex methods into research use, providing researchers with optimized immunofluorescence-based biomarker detection.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-10-09
Description

Vizgen and Ultivue merged in October 2024 to combine Vizgen's MERFISH spatial genomics platform with Ultivue's InSituPlex multiplex proteomic profiling, creating a unified spatial multiomics platform. The merger was accompanied by a Series D financing from ARCH Venture Partners, Northpond Ventures, and Tao Capital Partners. Rob Carson (former Ultivue CEO) became CEO of the combined entity. The integration positions Vizgen as a single-vendor provider of integrated spatial transcriptomics and proteomics solutions.

Strategic tierCoreTypeTechnology or Integration
Description

Integration partnership to unlock the potential of high-resolution spatial genomics data from MERSCOPE Ultra with BioTuring's SpatialX deep learning platform. The partnership provides researchers with a streamlined solution for analyzing complex spatial genomics data, enabling deeper insights into cellular interactions and tissue architecture. Includes joint webinar content.

Strategic tierCoreTypeGTM or Marketing Partner
Description

Strategic partnership to support the Human Cell Atlas mission of mapping every human cell type with high resolution and spatial context. Vizgen provides advanced spatial transcriptomics technology, exclusive HCA member discounts, and a new Cell Atlasing Hub central resource offering public datasets, case studies, and expert consultation to the HCA community.

Strategic tierCoreTypeTechnology or Integration
Description

Partnership to incorporate an end-to-end pathology workflow with InSituPlex multiplex immunofluorescence, enabling high-quality spatial proteomics within routine FFPE histology. InSituPlex assays preserve morphology, support same-slide H&E, and deliver reproducible quantitative spatial proteomics integrated with Leica's pathology imaging and digital review workflow.

Strategic tierCoreTypeTechnology or Integration
Description

Partnership to provide precise, high-resolution imaging and workflow integration enhancing multiplex immunofluorescence data. InSituPlex technology pairs with ZEISS advanced microscopy platforms (including Axioscan 7 and SlideStream) for optimized image acquisition, consistent signal quality, and smoother data handling within ZEISS digital workflows. Supports both standard InSituPlex and ZEISS-enabled automated mIF workflows.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Authorized distributor for Vizgen MERSCOPE Platform products in Switzerland. Office at Viaduktstrasse 42, 4051 Basel. Provides local sales, technical support, and order fulfillment for the Swiss market.

8CARLO ERBA Reagents srl
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Authorized distributor for Vizgen MERSCOPE Platform products in Italy. Office at Via R. Merendi, 22, 20007 Cornaredo MI, Italy.

vizgen.com
9Izasa Scientific
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Authorized distributor for Vizgen MERSCOPE Platform products in Spain and Portugal. Office at Calle Aragoneses, 13, 28108 Alcobendas, Madrid, Spain.

vizgen.com
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Authorized distributor for Vizgen MERSCOPE Platform products across Central and Eastern Europe (Czech Republic, Poland, Slovakia, Hungary, Romania). Headquartered at Služeb 4, Prague, Czech Republic.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Authorized distributor for Vizgen MERSCOPE Platform products in Japan. Office in Bunkyo-ku, Tokyo.

12Cosmo Bio Co., Ltd.
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Authorized distributor for Vizgen MERSCOPE Platform products in Japan. Office in Koto-ku, Tokyo.

vizgen.com
13Gene Company
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Authorized distributor for Vizgen MERSCOPE Platform products in Hong Kong. Office at 8/F Shell Industrial Building, Chai Wan, Hong Kong Island.

vizgen.com
14SINSAGE Technology Co., Ltd.
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Authorized distributor for Vizgen MERSCOPE Platform products in mainland China. Office at 27/F, Block B, China Railway Construction Plaza, Chaoyang District, Beijing.

vizgen.com
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Authorized distributor for Vizgen MERSCOPE Platform products in South Korea. Office in Gwangcheon-si, Gyeonggi-do.

16Integrated Sciences
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Authorized distributor for Vizgen MERSCOPE Platform products in Australia and New Zealand. Office at 54 Gibbes St, Chatswood NSW 2067, Australia.

vizgen.com
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Authorized distributor for Vizgen MERSCOPE Platform products in Taiwan. Office in Nangang Dist., Taipei City.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Authorized distributor for Vizgen MERSCOPE Platform products in Thailand (Bangkok) and Singapore.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Authorized distributor for Vizgen MERSCOPE Platform products in India. Headquarters in Perungudi, Chennai.

20Eldan Electronic Instruments Ltd.
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Authorized distributor for Vizgen MERSCOPE Platform products in Israel. Office in Petach-Tikva.

vizgen.com
21Sanderson Center for Optical Experimentation (SCOPE) at UMass Chan Medical School
Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Vizgen Certified Service Provider in Worcester, MA. Certified fee-for-service laboratory delivering MERSCOPE Platform spatial transcriptomics services on behalf of external researchers. Received latest training on Vizgen recommended wet lab and data analysis workflows.

vizgen.com
22Center for Spatial Multiomics (COSMO) at TGen / City of Hope
Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Vizgen Certified Service Provider in Phoenix, AZ. TGen's COSMO service center offers spatial multiomics services using Vizgen technology platforms to external research customers.

vizgen.com
Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Vizgen Certified Service Provider in Denver, CO. Certified for InSituPlex multiplex spatial proteomics services.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Vizgen Certified Service Provider in New York, NY. Provides fee-for-service spatial biology services on Vizgen platforms.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Vizgen Certified Service Provider in Little Rock, AR. Provides spatial biology services to external researchers using Vizgen technology.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Vizgen Certified Service Provider in Geneva, Switzerland. Provides fee-for-service spatial biology services to European research customers.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Vizgen Certified Service Provider in Norwich, United Kingdom. Single-cell and spatial analysis service provider.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Vizgen Certified Service Provider in Nottingham, United Kingdom. Provides histology and spatial biology services.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Vizgen Certified Service Provider in Seoul, South Korea. Provides spatial biology services in the APAC region using Vizgen technology.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

10x Genomics offers competing spatial transcriptomics platforms (Visium, Visium HD, Xenium) and is Vizgen's most direct head-to-head competitor in single-cell spatial genomics, also a former litigation counterparty.

TypeDirect peer
Description

NanoString's GeoMx digital spatial profiling and cosMx spatial molecular imager compete directly with MERFISH and InSituPlex, particularly in oncology and translational research workflows.

TypeDirect peer
Description

Akoya offers the PhenoCycler (formerly CODEX) and Phenoptics spatial proteomics platforms, competing with Vizgen's InSituPlex for spatial multiplex immunofluorescence workflows.

TypeBroad incumbent
Description

Bruker acquired NanoString's spatial biology assets and offers a broader portfolio of life-science instruments and proteomics platforms, providing incumbent reach that competes with Vizgen's spatial multiomics offering.

TypeBroad incumbent
Description

Bio-Techne's RNAscope in situ hybridization platform is a long-established spatial genomics incumbent in academic and translational labs, providing low-plex alternative workflows to MERFISH.

TypeBroad incumbent
Description

Illumina is the dominant next-generation sequencing platform provider and an adjacent incumbent in genomics; David Walt (Illumina founder) sits on Vizgen's SAB and the company represents the broader ecosystem in which Vizgen competes.

TypeBroad incumbent
Description

Standard BioTools offers mass cytometry and spatial multiomics-adjacent single-cell analysis platforms, competing with Vizgen for translational and immunology research budgets.

TypeOthers
Description

Leica Biosystems is a Vizgen technology partner integrating InSituPlex multiplex IF with Leica pathology imaging workflows, and represents the broader digital pathology ecosystem that competes for the same workflow budgets.

TypeOthers
Description

Hamamatsu is a strategic Vizgen partner for the MoxiePlex immunofluorescence imaging platform and a broader imaging/sensor incumbent in the spatial biology instrumentation stack.

10Carl Zeiss Microscopy
TypeOthers
Description

ZEISS is a Vizgen integration partner for InSituPlex workflows on Axioscan 7 and SlideStream, and is a broader microscopy incumbent whose imaging platforms can substitute or complement Vizgen's MERSCOPE Ultra.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile6 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration7 records

Each record includes

Title, Type, Description, Source

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vizgen

Spatial Multiomics Instrumentsvizgen.com

Vizgen provides integrated spatial multiomics platforms combining MERFISH 2.0 transcriptomics and InSituPlex proteomics on the MERSCOPE Ultra instrument, serving academic researchers, biopharma drug discovery teams, and core facilities worldwide.

What Vizgen does

Vizgen is a privately held spatial multiomics company headquartered in Waltham, Massachusetts, with R&D and lab services in Cambridge, MA. Founded in 2019 to commercialize MERFISH technology exclusively licensed from Harvard University, the company has built an integrated platform that combines spatial transcriptomics (MERFISH 2.0 chemistry on the MERSCOPE Ultra instrument) with spatial proteomics (InSituPlex multiplex immunofluorescence inherited from the October 2024 Ultivue merger), supported by AI-driven analysis (STARVUE) and an open-source cell-segmentation tool (VPT). The company sells capital equipment, recurring reagents and consumables, software licenses, professional services, and runs a global Certified Service Provider (CSP) network, with more than 200 MERSCOPE platforms installed across academic, healthcare, and biopharma customers worldwide and 400+ peer-reviewed MERFISH publications.

Vizgen serves four primary customer segments: academic neuroscience researchers, oncology and immuno-oncology labs, cell-atlasing consortia (including the Human Cell Atlas), and biopharma drug discovery and translational teams, with a secondary base of core facilities and CSPs. The go-to-market combines direct enterprise sales in the UK, BENELUX, Nordics, France, Germany, Austria, and Singapore with a global distributor network covering 14+ countries; revenue is generated through one-time instrument sales, recurring consumables and panel pull-through on the installed base, per-instrument software licensing (EULAs for MERSCOPE Vizualizer and instrument software), and project-based spatial omics services including a newly launched Volumetric Tissue Mapping offering. The company is venture-backed (most recent $48 million Series E in January 2026 led by ARCH Venture Partners) with institutional investors including ARCH, M Ventures, Northpond Ventures, Tao Capital Partners, and Novalis LifeSciences, and is led by CEO Rob Carson following the Ultivue merger.

The business model is a classic razor-and-blade life-sciences tools franchise anchored by a recurring consumables stream tied to the installed MERSCOPE instrument base, complemented by growing services revenue and a software-plus-AI roadmap (cloud-based MERFISH 2.0 analysis, an AI Analysis Agent for end-to-end workflow automation, and continued expansion of pre-designed gene and protein panels). The 2025 settlement of the 10x Genomics / Harvard patent litigation removed a major commercialization overhang, and the CEO has publicly stated Vizgen is on a path to profitability, though no specific timeline has been disclosed. Notable scientific and commercial endorsements come from the Allen Institute for Brain Science, UCSD / Ludwig Institute for Cancer Research, Mayo Clinic, Weizmann Institute of Science, St. Jude Children's Research Hospital, and SickKids Research Institute.

Vizgen firmographics

Firmographics
Name
Vizgen
Legal name
Vizgen, Inc.
Website
https://vizgen.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
101–250 employees
Short description
Vizgen provides integrated spatial multiomics platforms combining MERFISH 2.0 transcriptomics and InSituPlex proteomics on the MERSCOPE Ultra instrument, serving academic researchers, biopharma drug discovery teams, and core facilities worldwide.
Ownership category
akta.pro rank

Vizgen industry classification

Industry
Product category
Spatial Multiomics Instruments
NAICS
Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGANAC
Single-Cell & Spatial Omics Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGANAE
Transcriptomics & Gene Expression Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAF
Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Spatial transcriptomics platforms
  • Spatial proteomics assays
  • Single-cell spatial genomics
  • Multiplex immunofluorescence instruments
  • Spatial multiomics instruments

Where Vizgen is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Vizgen business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Instrument Sales (Capital Equipment): One-time sale of the MERSCOPE Ultra spatial genomics instrument to research institutions, biopharma, and certified service providers; gated by quote-based enterprise sales motion.
  2. Reagents and Consumables: Recurring revenue from MERSCOPE Gene Imaging Kits, MERSCOPE Slides, sample preparation kits, verification kits, InSituPlex protein assays, and pre-designed gene panels. Consumables attach to the installed MERSCOPE instrument base, providing high-margin pull-through.
  3. Software Licensing: Per-instrument and enterprise licensing for MERSCOPE Vizualizer visualization software (EULA) and MERSCOPE instrument/image-processing software (EULA), including Early Release purchase and license terms.
  4. Spatial Omics Lab Services: Professional services including spatial transcriptomics analysis services, spatial proteomics/assay development services, custom panel design services, and the new Volumetric Tissue Mapping service offering project-based access to MERFISH data generation.
  5. Certified Service Provider Network Revenue: Recurring revenue from CSP program participation: certified labs receive special CSP pricing tiers in exchange for delivering Vizgen spatial biology services to end customers, with co-branding opportunities to drive demand.

Pricing tiers

ModelBillingPrice
OtherAnnualQuote-based pricing across all product categories; not publicly disclosed

Go-to-market motion1 record

Distribution channels5 records

Marketing channels9 records

Vizgen product offering

Product offering

Core offering

Vizgen develops and sells an integrated spatial multiomics platform for research and translational use, anchored by the MERSCOPE Ultra instrument running MERFISH 2.0 chemistry for in situ single-cell spatial transcriptomics and complemented by InSituPlex multiplex immunofluorescence assays for spatial proteomics, STARVUE AI analysis, and Vizgen Post-processing Tool (VPT) cell segmentation. The company also markets gene panels (pre-designed and custom), reagents and consumables, visualization and analysis software, and fee-for-service spatial omics lab services.

Product overview

Vizgen offers an integrated spatial multiomics platform combining spatial transcriptomics and spatial proteomics, built on its proprietary MERFISH 2.0 chemistry and InSituPlex assays and powered by the AI-driven STARVUE analysis and Vizgen Post-processing Tool (VPT). The core instrument is the MERSCOPE Ultra Platform (with the original MERSCOPE Platform and MERSCOPE Vizualizer Software as the visualization layer), which runs Pre-designed Panels and customizable Add-on Gene Panels (including Mouse PanNeuro Cell Type, Pan Human, Pan Mouse, Human Brain, Human Breast Cancer, Human ImmunoOncology, Human Colon/Lung/Liver/Kidney Cancer, Mouse Transcription Factor A/B, and Tumor EMT/Inflammation/Cardiovascular panels in development). The proteomics arm uses InSituPlex multiplex immunofluorescence with OmniVUE pre-designed panels and U-VUE custom panels. Supporting offerings include the open-source VPT cell segmentation tool (with Cellpose-SAM and InstanSeg plugins), the Vizgen Gene Panel Design Portal, Volumetric Tissue Mapping services for 3D thick-tissue analysis, and Spatial Transcriptomics and Spatial Proteomics Lab Services for end-to-end project support. Together, these tools allow researchers to map up to 1,000 RNA targets and quantify proteins in whole-slide FFPE or fresh frozen tissue at single-cell resolution.

Differentiator

Problem solved

Functional benefit

Brands

  • MERSCOPE: Vizgen's flagship spatial transcriptomics platform / instrument family, including the MERSCOPE Ultra high-throughput instrument.
  • MERSCOPE Ultra
  • MERFISH
  • InSituPlex
  • STARVUE
  • MERSCOPE Vizualizer
  • OmniVUE

Products and services

  • MERSCOPE Ultra Platform

Quantifiable outcome

  • 200+ MERSCOPE Platforms installed globally (largest spatial biology install base)
  • +4 more outcomes

Companies that use Vizgen

Customer profile

Named customers9 records

Segments6 records

Ideal customer profiles6 records

Vizgen technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration7 records

AI capability8 records

Feature8 records

Vizgen partnerships and signals

Strategic signal

Partnerships

29 partnerships are on record, tiered flagship and core.

  • HamamatsuflagshipTechnology or Integration · 3 June 2025Strategic partnership to streamline spatial biology workflows and deliver biomarker-detecting imaging. Collaboration centers on immunofluorescence imaging using Hamamatsu's MoxiePlex platform integrated with Vizgen's spatial transcriptomics and proteomics solutions. The partnership is intended to help translate multiplex methods into research use, providing researchers with optimized immunofluorescence-based biomarker detection.
  • Ultivue, Inc.flagshipStrategic or Co-development Partner · 9 October 2024Vizgen and Ultivue merged in October 2024 to combine Vizgen's MERFISH spatial genomics platform with Ultivue's InSituPlex multiplex proteomic profiling, creating a unified spatial multiomics platform. The merger was accompanied by a Series D financing from ARCH Venture Partners, Northpond Ventures, and Tao Capital Partners. Rob Carson (former Ultivue CEO) became CEO of the combined entity. The integration positions Vizgen as a single-vendor provider of integrated spatial transcriptomics and proteomics solutions.
  • BioTuringcoreTechnology or IntegrationIntegration partnership to unlock the potential of high-resolution spatial genomics data from MERSCOPE Ultra with BioTuring's SpatialX deep learning platform. The partnership provides researchers with a streamlined solution for analyzing complex spatial genomics data, enabling deeper insights into cellular interactions and tissue architecture. Includes joint webinar content.
  • Human Cell Atlas (HCA)coreGTM or Marketing PartnerStrategic partnership to support the Human Cell Atlas mission of mapping every human cell type with high resolution and spatial context. Vizgen provides advanced spatial transcriptomics technology, exclusive HCA member discounts, and a new Cell Atlasing Hub central resource offering public datasets, case studies, and expert consultation to the HCA community.
  • Leica BiosystemscoreTechnology or IntegrationPartnership to incorporate an end-to-end pathology workflow with InSituPlex multiplex immunofluorescence, enabling high-quality spatial proteomics within routine FFPE histology. InSituPlex assays preserve morphology, support same-slide H&E, and deliver reproducible quantitative spatial proteomics integrated with Leica's pathology imaging and digital review workflow.
  • ZEISS MicroscopycoreTechnology or IntegrationPartnership to provide precise, high-resolution imaging and workflow integration enhancing multiplex immunofluorescence data. InSituPlex technology pairs with ZEISS advanced microscopy platforms (including Axioscan 7 and SlideStream) for optimized image acquisition, consistent signal quality, and smoother data handling within ZEISS digital workflows. Supports both standard InSituPlex and ZEISS-enabled automated mIF workflows.
  • Bucher Biotec AGcoreChannel Partner/ Reseller/ DistributorAuthorized distributor for Vizgen MERSCOPE Platform products in Switzerland. Office at Viaduktstrasse 42, 4051 Basel. Provides local sales, technical support, and order fulfillment for the Swiss market.
  • CARLO ERBA Reagents srlcoreChannel Partner/ Reseller/ DistributorAuthorized distributor for Vizgen MERSCOPE Platform products in Italy. Office at Via R. Merendi, 22, 20007 Cornaredo MI, Italy.
  • Izasa ScientificcoreChannel Partner/ Reseller/ DistributorAuthorized distributor for Vizgen MERSCOPE Platform products in Spain and Portugal. Office at Calle Aragoneses, 13, 28108 Alcobendas, Madrid, Spain.
  • AccelacoreChannel Partner/ Reseller/ DistributorAuthorized distributor for Vizgen MERSCOPE Platform products across Central and Eastern Europe (Czech Republic, Poland, Slovakia, Hungary, Romania). Headquartered at Služeb 4, Prague, Czech Republic.
  • PrimetechcoreChannel Partner/ Reseller/ DistributorAuthorized distributor for Vizgen MERSCOPE Platform products in Japan. Office in Bunkyo-ku, Tokyo.
  • Cosmo Bio Co., Ltd.coreChannel Partner/ Reseller/ DistributorAuthorized distributor for Vizgen MERSCOPE Platform products in Japan. Office in Koto-ku, Tokyo.
  • Gene CompanycoreChannel Partner/ Reseller/ DistributorAuthorized distributor for Vizgen MERSCOPE Platform products in Hong Kong. Office at 8/F Shell Industrial Building, Chai Wan, Hong Kong Island.
  • SINSAGE Technology Co., Ltd.coreChannel Partner/ Reseller/ DistributorAuthorized distributor for Vizgen MERSCOPE Platform products in mainland China. Office at 27/F, Block B, China Railway Construction Plaza, Chaoyang District, Beijing.
  • MDxK InccoreChannel Partner/ Reseller/ DistributorAuthorized distributor for Vizgen MERSCOPE Platform products in South Korea. Office in Gwangcheon-si, Gyeonggi-do.
  • Integrated SciencescoreChannel Partner/ Reseller/ DistributorAuthorized distributor for Vizgen MERSCOPE Platform products in Australia and New Zealand. Office at 54 Gibbes St, Chatswood NSW 2067, Australia.
  • Blossom BiocoreChannel Partner/ Reseller/ DistributorAuthorized distributor for Vizgen MERSCOPE Platform products in Taiwan. Office in Nangang Dist., Taipei City.
  • Genomax TechnologiescoreChannel Partner/ Reseller/ DistributorAuthorized distributor for Vizgen MERSCOPE Platform products in Thailand (Bangkok) and Singapore.
  • Spinco Biotech Pvt. Ltd.coreChannel Partner/ Reseller/ DistributorAuthorized distributor for Vizgen MERSCOPE Platform products in India. Headquarters in Perungudi, Chennai.
  • Eldan Electronic Instruments Ltd.coreChannel Partner/ Reseller/ DistributorAuthorized distributor for Vizgen MERSCOPE Platform products in Israel. Office in Petach-Tikva.
  • Sanderson Center for Optical Experimentation (SCOPE) at UMass Chan Medical SchoolcoreImplementation/ SI/ Consulting PartnerVizgen Certified Service Provider in Worcester, MA. Certified fee-for-service laboratory delivering MERSCOPE Platform spatial transcriptomics services on behalf of external researchers. Received latest training on Vizgen recommended wet lab and data analysis workflows.
  • Center for Spatial Multiomics (COSMO) at TGen / City of HopecoreImplementation/ SI/ Consulting PartnerVizgen Certified Service Provider in Phoenix, AZ. TGen's COSMO service center offers spatial multiomics services using Vizgen technology platforms to external research customers.
  • Lanterne DxcoreImplementation/ SI/ Consulting PartnerVizgen Certified Service Provider in Denver, CO. Certified for InSituPlex multiplex spatial proteomics services.
  • HistoWizcoreImplementation/ SI/ Consulting PartnerVizgen Certified Service Provider in New York, NY. Provides fee-for-service spatial biology services on Vizgen platforms.
  • Arkana LaboratoriescoreImplementation/ SI/ Consulting PartnerVizgen Certified Service Provider in Little Rock, AR. Provides spatial biology services to external researchers using Vizgen technology.
  • Fondation Campus Biotech Geneva (FCBG)coreImplementation/ SI/ Consulting PartnerVizgen Certified Service Provider in Geneva, Switzerland. Provides fee-for-service spatial biology services to European research customers.
  • Earlham InstitutecoreImplementation/ SI/ Consulting PartnerVizgen Certified Service Provider in Norwich, United Kingdom. Single-cell and spatial analysis service provider.
  • HistologiXcoreImplementation/ SI/ Consulting PartnerVizgen Certified Service Provider in Nottingham, United Kingdom. Provides histology and spatial biology services.
  • Portrai Inc.coreImplementation/ SI/ Consulting PartnerVizgen Certified Service Provider in Seoul, South Korea. Provides spatial biology services in the APAC region using Vizgen technology.

Scale indicators10 records

Recent moves6 records

Expansion highlights7 records

Vizgen competitors and assessment

Company assessment

Direct peers

  • 10x Genomics: 10x Genomics offers competing spatial transcriptomics platforms (Visium, Visium HD, Xenium) and is Vizgen's most direct head-to-head competitor in single-cell spatial genomics, also a former litigation counterparty.
  • NanoString Technologies (a Bruker company): NanoString's GeoMx digital spatial profiling and cosMx spatial molecular imager compete directly with MERFISH and InSituPlex, particularly in oncology and translational research workflows.
  • Akoya Biosciences: Akoya offers the PhenoCycler (formerly CODEX) and Phenoptics spatial proteomics platforms, competing with Vizgen's InSituPlex for spatial multiplex immunofluorescence workflows.

Broad incumbents

  • Bruker Corporation: Bruker acquired NanoString's spatial biology assets and offers a broader portfolio of life-science instruments and proteomics platforms, providing incumbent reach that competes with Vizgen's spatial multiomics offering.
  • Bio-Techne: Bio-Techne's RNAscope in situ hybridization platform is a long-established spatial genomics incumbent in academic and translational labs, providing low-plex alternative workflows to MERFISH.
  • Illumina: Illumina is the dominant next-generation sequencing platform provider and an adjacent incumbent in genomics; David Walt (Illumina founder) sits on Vizgen's SAB and the company represents the broader ecosystem in which Vizgen competes.
  • Standard BioTools (formerly Fluidigm): Standard BioTools offers mass cytometry and spatial multiomics-adjacent single-cell analysis platforms, competing with Vizgen for translational and immunology research budgets.

Others

  • Leica Biosystems: Leica Biosystems is a Vizgen technology partner integrating InSituPlex multiplex IF with Leica pathology imaging workflows, and represents the broader digital pathology ecosystem that competes for the same workflow budgets.
  • Hamamatsu Photonics: Hamamatsu is a strategic Vizgen partner for the MoxiePlex immunofluorescence imaging platform and a broader imaging/sensor incumbent in the spatial biology instrumentation stack.
  • Carl Zeiss Microscopy: ZEISS is a Vizgen integration partner for InSituPlex workflows on Axioscan 7 and SlideStream, and is a broader microscopy incumbent whose imaging platforms can substitute or complement Vizgen's MERSCOPE Ultra.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Vizgen social profiles

Digital presence

Vizgen compliance and trust

Trust signal

Compliance2 records

Vizgen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vizgen leadership team

Management profile

Number of profiles

Profiles10 records

Vizgen subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Vizgen funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vizgen M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vizgen

What does Vizgen do?

Vizgen develops and sells an integrated spatial multiomics platform for research and translational use, anchored by the MERSCOPE Ultra instrument running MERFISH 2.0 chemistry for in situ single-cell spatial transcriptomics and complemented by InSituPlex multiplex immunofluorescence assays for spatial proteomics, STARVUE AI analysis, and Vizgen Post-processing Tool (VPT) cell segmentation. The company also markets gene panels (pre-designed and custom), reagents and consumables, visualization and analysis software, and fee-for-service spatial omics lab services.

Is Vizgen a public or private company?

Vizgen is a private company. It is classified as venture growth investor backed and is currently operating.

When was Vizgen founded?

Vizgen was founded in 2019. It employs 101 to 250 people.

Where is Vizgen based?

Vizgen is headquartered in Cambridge, United States, in the North America region.

How does Vizgen make money?

Five revenue lines are on record. Instrument Sales (Capital Equipment) is the primary driver. The others are reagents and Consumables, software Licensing, spatial Omics Lab Services and certified Service Provider Network Revenue.

Who are Vizgen's main competitors?

Direct peers on record are 10x Genomics, NanoString Technologies (a Bruker company) and Akoya Biosciences. Broad incumbents are Bruker Corporation, Bio-Techne, Illumina and Standard BioTools (formerly Fluidigm). Others are Leica Biosystems, Hamamatsu Photonics and Carl Zeiss Microscopy.

Does Vizgen have an API?

No public API is recorded for Vizgen.

What industry is Vizgen in?

Vizgen's product category is Spatial Multiomics Instruments. Its primary akta.pro industry code is HLAGANAC, Single-Cell & Spatial Omics Services, with a secondary code of HLAGANAE, Transcriptomics & Gene Expression Profiling Services. Its NAICS code is 334516 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogVizgen® Launches Velocity Lab™ for AI-Scale Spatial Biology ResearchVizgen launched Velocity Lab, a spatial biology foundry generating data at foundation-model scale. It offers Volumetric Tissue Mapping profiling up to 100 µm tissue depth and MERSCOPE CoMap for RNA-protein co-detection. The platform scales toward transcriptome-scale profiling of hundreds of millions of cells per week by 2027.Labroots Trending Science NewsFrom Atlas to Action: Going Deeper in the Next Era of Spatial BiologyVizgen's scientific co-founders argue that the field of spatial biology is transitioning from an atlas-building era focused on breadth to a new phase emphasizing decision-grade data with spatial precision and biological fidelity. The company's MERSCOPE platform enables volumetric tissue mapping and multiplexed protein imaging capabilities that allow researchers to identify cell populations and functional tissue neighborhoods previously missed by two-dimensional approaches. The authors contend this shift from exploratory to decision-grade spatial data enables the translation of atlas observations into actionable insights for drug target selection and biomarker discovery.BioSpaceVizgen® to Advance Cell Atlases with New Volumetric Tissue Mapping Spatial Data and Services at HCA 2026 MeetingVizgen will debut Volumetric Tissue Mapping datasets in mouse and human neurodegenerative brain tissue at the HCA General Meeting in June 2026. The company also launches Volumetric Tissue Mapping services and a Cell Atlasing Hub. Extension into human cancer tissue is underway.Stanford University School of EngineeringExploring Spatial Biology with MERSCOPEVizgen hosted its December 2 MERSCOPE User Group Meeting, showcasing recent advances in spatial transcriptomics and upcoming technology improvements. The event featured presentations from Stanford researchers demonstrating the platform's application in studying brain development, glaucoma, aging, and neural circuits, alongside a launch announcement for next-generation MERSCOPE Ultra and MERFISH 2.0 tools.GenengnewsOmics in Orlando Day 2: A Video Report from AGBTAt the AGBT (Advances in Genome Biology and Technology) meeting in Orlando, GEN editors Julianna LeMieux and Kevin Davies discussed key announcements from the conference in a video debrief. Notable product launches and announcements included Vizgen's focus on spatial and organoids, Illumina's TruPath Genome product (formerly Constellation mapped reads), Bruker's spatial imaging tools CellScape and PaintScape, and 10x Genomics' updates. The article promotes an upcoming GEN Live event on March 2 featuring expert commentary on the AGBT announcements.Business Wire BlogVizgen to Debut Spatial Multi-Omics Roadmap at AGBT 2026Vizgen, Inc. announced a series of planned innovations and a technology roadmap at the AGBT General Meeting in Orlando, Florida, including enhancements to its MERSCOPE Ultra platform, new MERSCOPE Add-On Genes customization capabilities, and optimized MERSCOPE slides with streamlined pre-analytical workflows. The company is also developing cloud-based image analysis platforms for MERFISH 2.0 data, advanced segmentation algorithms, and thick tissue 3D spatial biology imaging capabilities targeting drug discovery and organoid research. Vizgen stated these developments align with broader regulatory and research community interest in alternative model systems, with a pipeline presentation scheduled for February 23-26, 2026.Market ScoopSingle-Cell Omics MarketA market research report projects the global Single-Cell Omics Market will grow from US$2.1 billion in 2024 to US$9.4 billion by 2034, representing a compound annual growth rate of 16.2%, driven by increasing adoption of single-cell technologies in oncology, immunology, and neuroscience research. In recent developments, Pacific Biosciences expanded its PacBio Onso sequencing system into the 10x Genomics Compatible Partner Program in October 2024, while Vizgen and Ultivue announced a merger to unify their spatial biology capabilities. Additionally, Roche led a $257 million funding round for Freenome in February 2024 to advance early cancer detection using multi-omics platforms.Pulse 2.0Vizgen: $48 Million Funding Raised To Scale Spatial Multi-Omics PlatformVizgen, a spatial multi-omics company, announced it has closed a $48 million financing round led by ARCH Venture Partners and co-led by M Ventures and Northpond Ventures, with participation from existing investors. The funding follows the resolution of prior litigation and will support the company's innovation roadmap, global expansion of its research services, scaling of manufacturing operations, and efforts to move toward profitability. The capital will also support launches of newer products including MERSCOPE Ultra and MERFISH 2.0 chemistry as demand for spatial biology tools grows in basic research and drug discovery.FinSMEsVizgen Raises $48M in FundingVizgen, a Waltham, MA-based spatial multi-omics company, raised $48 million in funding in a round led by ARCH Venture Partners, M Ventures, and Northpond Ventures. The company plans to use the proceeds to expand its global research service capabilities and scale its manufacturing operations. Vizgen's technologies include the MERFISH 2.0 platform and MERSCOPE Platform for single-cell spatial genomics, as well as InSituPlex protein assays and STARVUE spatial image analysis technology.citybizVizgen Raises $48M With Support From ARCH, M Ventures, and NorthpondVizgen, a spatial multi-omics company, closed a $48 million financing round led by ARCH Venture Partners with participation from M Ventures and Northpond Ventures. The funding will be used to expand global researcher reach, scale manufacturing operations, and execute on the company's innovation roadmap, with CEO Rob Carson noting the company is now on a path to profitability following resolution of prior litigation. Since late 2024, Vizgen has launched MERFISH 2.0 chemistry, expanded proteomics offerings, published over 100 peer-reviewed articles, and established strategic partnerships in academia and industry.